机械化学消融治疗小隐静脉功能不全的五年随访
3年和5年免于再通率分别为84.7%和66.5%,免于再干预率分别为86.7%和72.6%。VCSS和AVVQ评分在1年内下降,但随后逐年上升,多因素分析显示BMI>25 kg/m2和术前SSV直径>6 mm是再通的显著危险因素。
要点
- MOCA治疗SSV功能不全5年再通率较高,免于再通率仅66.5%。
- 术后1年后生活质量进行性下降,VCSS和AVVQ评分逐年升高。
- BMI>25 kg/m2和术前SSV直径>6 mm是再通的独立危险因素。
核心结论
- MOCA治疗SSV功能不全的5年再通率和再干预率较高。
- 患者报告结局随时间恶化,生活质量进行性下降。
主要发现
- 3年免于再通率为84.7%,5年免于再通率为66.5%。
- 3年免于再干预率为86.7%,5年免于再干预率为72.6%。
- AVVQ评分从1年中位数5.0(IQR 3.0, 7.0)升至3年8.2(IQR 5.0, 11.0)和5年10.1(IQR 6.0, 14.0),p < .001。
- 多因素分析显示BMI > 25 kg/m2和术前SSV直径 > 6 mm是SSV再通的显著危险因素。
临床怎么用
- MOCA治疗SSV功能不全后需长期随访,关注再通和再干预风险。
- 对BMI>25 kg/m2或术前SSV直径>6 mm的患者应加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to assess the effectiveness of mechanochemical ablation (MOCA) for the treatment of small saphenous vein (SSV) incompetence at 3 and 5 years, building on preliminary results that showed feasibility, safety, and high occlusion rates at 1 year follow up. METHODS: Sixty patients who underwent MOCA for SSV incompetence at a single centre between January 2017 and December 2019 were included. Clinical and radiological data were reviewed retrospectively from a prospectively maintained database. Primary endpoints were SSV recanalisation and re-intervention at 3 and 5 years. Additional outcome measures included Venous Clinical Severity Score (VCSS), quality of life (QoL) using the Aberdeen Varicose Vein Questionnaire (AVVQ) and the visual analogue scale to assess pain during long term follow up, and signs and symptoms of chronic venous disease. Uni- and multivariable analyses were performed to identify risk factors for SSV recanalisation. RESULTS: Fifty patients completed the full 5 year follow up. Freedom from recanalisation was 84.7% at 3 years and 66.5% at 5 years. Freedom from re-intervention at the same time points was 86.7% and 72.6%, respectively. Although the VCSS and AVVQ scores decreased during the first year, a progressive increase was observed over the follow up period. The median VCSS increased significantly at 3 and 5 years. The AVVQ score increased from a median (interquartile range [IQR]) of 5.0 (IQR 3.0, 7.0) at 1 year to 8.2 (IQR 5.0, 11.0) at 3 years and 10.1 (IQR 6.0, 14.0) at 5 years (p < .001). Multivariable analysis identified body mass index > 25 kg/m2 and pre-operative SSV diameter > 6 mm as significant risk factors for SSV recanalisation. CONCLUSION: Treatment of SSV incompetence with MOCA had high 5 year recanalisation and re-intervention rates. Additionally, a progressive decrease in QoL and deterioration of patient reported outcomes over time were found, as reflected by rising VCSS and AVVQ scores.
引用
- Baccellieri D, Ardita V, Valente FBA, et al. Five Year Follow Up of Mechanochemical Ablation for the Treatment of Small Saphenous Vein Incompetence. Eur J Vasc Endovasc Surg. 2026. PMID: 41850563. doi:10.1016/j.ejvs.2026.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。